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OBJECTIVES: To evaluate the effects of combined treatment with granulocyte colony-stimulating factor (G-CSF)
and methylprednisolone in rats subjected to experimental spinal cord injury.
METHODS: Forty Wistar rats received a moderate spinal cord injury and were divided into four groups: control
(no treatment); G-CSF (G-CSF at the time of injury and daily over the next five days); methylprednisolone
(methylprednisolone for 24 h); and G-CSF/Methylprednisolone (methylprednisolone for 24 h and G-CSF at the
time of injury and daily over the next five days). Functional evaluation was performed using the Basso, Beattie
and Bresnahan score on days 2, 7, 14, 21, 28, 35 and 42 following injury. Motor-evoked potentials were evaluated.
Histological examination of the spinal cord lesion was performed immediately after euthanasia on day 42.
RESULTS: Eight animals were excluded (2 from each group) due to infection, a normal Basso, Beattie and
Bresnahan score at their first evaluation, or autophagy, and 32 were evaluated. The combination of
methylprednisolone and G-CSF promoted greater functional improvement than methylprednisolone or G-CSF
alone (po0.001). This combination also exhibited a synergistic effect, with improvements in hyperemia and
cellular infiltration at the injury site (po0.001). The groups displayed no neurophysiological differences
(latency p=0.85; amplitude p=0.75).
CONCLUSION: Methylprednisolone plus G-CSF promotes functional and histological improvements superior to
those achieved by either of these drugs alone when treating spinal cord contusion injuries in rats. Combining
the two drugs did have a synergistic effect.
KEYWORDS: Spinal Cord Injuries; Wistar Rats; Granulocyte Colony-Stimulating Factor; Methylprednisolone.
’ INTRODUCTION
Researchers worldwide struggle to find evidence of sub-
stances or procedures that can reduce the devastating con-
sequences of spinal cord injuries, which affect up to 80 per
million people worldwide, with 500,000 new cases per year
(1). Most research is focused on surgical treatment, rehabi-
litation or physical training and particularly on pharmaco-
logical therapies aimed at restoring neuronal plasticity and
function by reducing the effects of secondary lesions and
stimulating tissue regeneration (2-5). Estrogen has been found
to reduce pro-inflammatory activity and protect neurons (6,7).
The antioxidant effect of melatonin has also been extensively
investigated, but only in low-quality experimental studies (8).
Methylprednisolone has proven clinically effective (9,10); how-
ever, its use as a first-line treatment has recently been que-
stioned due to the high incidence of complications and adverse
events, especially when higher doses are used (11). The use of
methylprednisolone has thus been reevaluated (12) but is still
widely accepted (13). Stem-cell transplantation (14,15) has also
been investigated.
Granulocyte colony-stimulating factor (G-CSF) is a glyco-
protein that acts as a growth-stimulating factor for hema-
topoietic progenitor cells (16,17). G-CSF is used to treat
neutropenia and to mobilize hematopoietic stem cells in
cases of bone marrow transplantation (16). Studies show that
G-CSF also has non-hematopoietic functions and that it can
increase tissue regeneration in organs such as the brain and
heart (17,18).DOI: 10.6061/clinics/2018/e235
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G-CSF has also been shown to produce neurological
improvements in experimental models of spinal cord injury
(17,19-21). In the acute phase of injury, G-CSF mobilized
bone marrow cells to the injured spinal cord, where it
suppressed neuronal and oligodendrocyte apoptosis, the
expression of inflammatory cytokines such as tumor necrosis
factor-alpha (TNF-a) and interleukin-1 beta (IL-1 beta) (22),
and lipid peroxidation (23), in addition to stimulating the
production of neurotrophic factors (21). In the subacute
phase of traumatic spinal cord injury, G-CSF stimulated
angiogenesis (24) and suppressed glial scar formation (25). In
two phase I/IIa studies, some neurological recovery was
observed in most patients with spinal cord injuries (26,27).
It is also possible that some drugs may act synergistically
to alleviate spinal cord injury (28), and synergy between
pharmacological and physical factors may improve trauma
recovery (2,29). Indeed, the best strategy in situations with a
complex pathophysiology, as in the case of spinal cord injury,
likely involves treatments that employ different pathogenic
mechanisms (29). However, no study has yet investigated the
effects of combining methylprednisolone and G-CSF, which
can be investigated using an experimental model of spinal
cord injury in rats.
Therefore, our objective was to evaluate the effects of
G-CSF associated with methylprednisolone on functional,
neurophysiological and histological outcomes in a standar-
dized experimental rat model of spinal cord injury.
’ MATERIALS AND METHODS
Ethics
This experimental study was carried out in strict accor-
dance with all international guidelines on handling and
controlling pain or suffering in the care and use of animals in
research. According to our laboratory protocols, all animals
are handled and stimulated to move prior to the experiments
so that they can become accustomed to the researchers and to
the motor function evaluation procedures. Ad libitum feeding
and hydration are maintained during studies carried out in
the lab, and appropriate cages (40 x 60 cm) and housing are
provided, with a maximum of five animals per cage in a space
with controlled temperature and humidity. The animals were
submitted to surgical and experimental procedures and were
euthanized under general anesthesia.
The study protocol was evaluated and approved by the
Research Ethics Committee of the institution (Comissão Cien-
tífica do Instituto de Ortopedia e Traumatologia e pela
Comissão de Ética para Análise de Projetos de Pesquisa do
Hospital das Clínicas da Faculdade de Medicina da Uni-
versidade de São Paulo (CAPPesq – HC-FMUSP; permit
number: IOT no. 965).
Study design, sample size and experimental animals
This is a controlled study with Wistar rats, which were
divided into four groups. Sample size was based on previ-
ously published studies using approximately 10 animals per
group (9,29). In total, 40 male Wistar rats, aged 20 to 21
weeks old and initially weighing 300 to 340 g, were used.
All animals came from the same university vivarium and
were weighed at the beginning and at the end of the study.
All rats were clinically evaluated at baseline to ensure that
they had normal motricity and good health. Animals with
macroscopic evidence of abnormalities in the spinal cord
or functional problems were excluded. Animals that died
shortly after the experimental spinal cord lesion, or animals
with autophagy or mutilation behaviors, were also excluded
from the study. Normal motricity (21 points on the Basso,
Beattie and Bresnahan (BBB) scale), even after the experi-
mental spinal cord lesion, was also an exclusion criterion,
since normal functioning indicated that the procedure failed.
The 40 animals were randomly allocated (using sequence
generator software and a ratio of 1:1:1:1) into five groups,
with 10 animals per group. The Control Group (CG) received
no treatment at all after the experimental spinal cord injury.
The Methylprednisolone Group (MG) was treated with
30 mg/kg of intravenous methylprednisolone at 10 min, 6 h
and 24 h after the spinal cord lesion, according to the pro-
tocol described by Park et al. (30). The G-CSF group received
treatment with 15 mcg/kg of subcutaneous G-CSF after the
lesion was induced and then daily for 5 days, according
to the method described by Kawabe et al. (24). Finally, the
G-CSF-M group received G-CSF at the moment the experi-
mental lesion was induced, followed by daily treatment with
G-CSF for 5 days, as well as methylprednisolone 24 h after
the lesion was induced. G-CSF and methylprednisolone were
provided at 10 min, 6 h and 24 h after the spinal cord lesions
were given to this group, at the same doses used for the other
two groups
Procedures
All animals were operated on by a single surgeon. The
animals were anesthetized using 50 mg/kg of pentobarbital
administered intraperitoneally. The anesthetic effect was
expected to begin within five minutes and to last approxi-
mately two hours, which was long enough for the spinal cord
injury procedure to be carried out. The level of anesthesia was
determined by evaluating the withdrawal reflex to tail com-
pression. After spinal cord injury, the animals were treated
with oral tramadol (15 mg/kg) dissolved in water (31).
All animals underwent a laminectomy under anesthesia.
A moderate contusion spinal cord lesion was produced at
T10, as described previously (29), using an NYU-Impactor
device with a 10-g impact rod from a 12.5 mm-height to com-
press the spinal cord for 15 s. This procedure produced a
spinal cord lesion that created loss of locomotor function.
After surgery and spinal cord lesion, the animals were
transferred to chambers with controlled temperature (25oC to
28oC), where they remained for 30 min. The bladders were
emptied by external compression. Antibiotic prophylaxis was
performed with cephalothin administered subcutaneously
(25 mg/kg) immediately after the lesion and once a day for
seven subsequent days. All rats were kept in the same viva-
rium and under the same controlled environmental conditions
for 42 days before being euthanized by a lethal dose of pen-
tobarbital (140 mg/kg).
The spinal cord was removed for necropsy. A segment
from T8 to T12 (approximately 2.5 cm-long) was fixed and
prepared for histological analysis as described previously
(29). Axial slices were cut 2 mm apart to span the injured
area and were extended 1 cm proximally and caudally from
the center of the lesion. After fixation and production of
paraffin blocks, 5-mm-thick sections were produced and
stained with hematoxylin-eosin for histological evaluation.
Outcomes evaluation
The pathologist responsible for the histological analysis (not
one of the authors), who was blinded to the experimental
2
G-CSF and methylprednisolone in SCI
Teixeira WG et al.
CLINICS 2018;73:e235
groups, scored the sections for the presence of necrosis, hemo-
rrhage, hyperemia, neural tissue degeneration, and infiltrate
as follows: 0 (absent), 1 (mild), 2 (moderate) and 3 (extensive).
Function was evaluated using the BBB rating scale
(29,32,33). This 21-point scale ranges from complete para-
plegia (score 0) to normal neurological function (score 21)
and was applied for 4 to 5 min on days 2, 7, 14, 21, 28, 35,
and 42 after spinal cord lesioning. The BBB score on the 42nd
day after injury was assessed simultaneously by two trained
observers who were blinded to experimental conditions and
to each other’s evaluations. In cases of disagreement, the
lower score was recorded for analysis.
On the 42nd day after lesioning, anesthetized rats (pento-
barbital, 50 mg/kg) underwent a motor evoked potential
(MEP) exam according to the method of Letaif et al. (6),
which was performed by a researcher who was blinded to
the experimental conditions, with electrodes positioned in
the semitendinosus and the biceps muscles of the thigh.
Amplitude and latency data were recorded.
Statistical analysis
Data are presented as means and standard deviations in
the descriptive analysis. The primary outcome of this study
was the BBB score on the 42nd day after injury. The histo-
logical variables and MEP results were secondary outcomes.
For inferential statistics, the data behaviors were observed
for possible outliers. Once identified, outliers were submitted
to the Dixon Q test for possible rejection. Subsequently, the
data were subjected to the Kolmogorov-Smirnov normality
test. If the data showed a normal distribution, parametric
tests, e.g., Student’s t-test and analysis of variance (ANOVA),
were performed. The number of factors was adjusted for
each situation. Parametric analysis was also performed when
the distribution was asymmetric. When the asymmetry was
to the right, the data were transformed by logarithm to the
base of 10, and when it was to the left, the data were raised to
the square.
The BBB scores were compared using a mixed effects
model with two factors, four groups and six weeks of eval-
uation, while considering repeated measures over time.
A possible effect of interaction between these factors was
also evaluated. The mixed effects model was adjusted by
considering matrices of equal covariance in the different
groups, as well as in unstructured form.
For the MEP results, the distribution of amplitude and
latency data was initially compared between the four groups
using the Kruskal-Wallis test. Next, ANOVA was used to
compare the amplitude and latency means in different
groups. The histological variables were also compared
between groups using the Kruskal-Wallis test.
We started with a null hypothesis considering a 5% pro-
bability of type I error. Statistical analyses were performed
using the Statistical Package for Social Sciences (SPSS),
version 19.0zx.
’ RESULTS
A total of 40 animals were operated on, but two rats had
to be excluded from each group. In the CG, one rat was
excluded due to failure of the experimental lesion (i.e., the rat
showed normal function after the procedure), and the second
was excluded for autophagy on the 22nd postoperative day.
Table 1 - Basso, Beattie, and Bresnahan (BBB) rating scores for hindlimbs, according to the evaluation times after spinal cord injury:
mean, minimum (min) and maximum (max) values, standard deviations (SD), degrees of freedom (DF) and results of the chi-squared
and Kruskal-Wallis tests.
Day Group N Mean SD Min Max v2 DF p
2 CG 16 0.31 0.60 0.0 2.0 0.905 3 0.824
MG 16 0.31 0.60 0.0 2.0
G-CSF 16 0.50 0.73 0.0 2.0
G-CSF-M 16 0.44 0.73 0.0 2.0
CG 16 1.69 2.89 0.0 9.0
7 MG 16 1.13 0.62 0.0 3.0 4.938 3 0.176
G-CSF 16 0.63 0.89 0.0 2.0
G-CSF-M 16 1.00 1.71 0.0 5.0
14 CG 16 4.94 2.11 1.0 8.0 16.634 3 0.001
MG 16 4.38 2.33 1.0 9.0
G-CSF 16 3.13 1.59 1.0 5.0
G-CSF-M 16 6.38 1.78 3.0 8.0
21 CG 16 6.06 2.69 2.0 11.0 16.126 3 0.001
MG 16 7.63 3.32 1.0 14.0
G-CSF 16 5.44 1.71 2.0 8.0
G-CSF-M 16 8.81 2.14 5.0 12.0
28 CG 16 6.88 2.39 4.0 11.0 21.408 3 o0.001
MG 16 9.56 1.82 7.0 12.0
G-CSF 16 7.88 1.36 5.0 10.0
G-CSF-M 16 11.38 3.46 5.0 15.0
35 CG 16 7.56 2.78 5.0 12.0 21.204 3 o0.001
MG 16 10.13 1.63 8.0 12.0
G-CSF 16 9.31 1.62 8.0 12.0
G-CSF-M 16 13.19 3.37 8.0 18.0
42 CG 16 8.69 2.09 6.0 12.0 21.644 3 o0.001
MG 16 11.00 1.83 8.0 14.0
G-CSF 16 10.38 1.59 8.0 12.0
G-CSF-M 16 14.13 3.59 8.0 18.0
CG = control group; MG = methylprednisolone group; G-CSF = granulocyte colony-stimulating factor group and G-CSF-M = group receiving G-CSF and
methylprednisolone.
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In the MG group, animals were excluded due to infection
on the 8th and 10th postoperative days. In the G-CSF group,
one animal was excluded due to lesion failure (i.e., normal
BBB) and the other due to infection on the 5th postoperative
day. Finally, in the G-CSF-M group, animals were excluded
due to lesion failure and autophagy (on the 10th post-
operative day).
The final sample consisted of eight animals in each group
and therefore 16 limbs. Because the BBB scores in both limbs
of the same animal were considered equivalent, Table 1
shows the data on the BBB evaluation for 16 cases per group
at seven evaluation times. From the 14th day on, the BBB
scores differed significantly among the groups. The highest
score was obtained in the G-CSF-M group, with a difference
of 1.44 points on the 14th day and 5.44 on the 42nd day from
the score in the CG (untreated). Multiple (post-hoc) compa-
risons are shown in Table 2 and confirm the superior reco-
very of the G-CSF-M group.
Because the MEP results were also equivalent in the
forelimbs and hindlimbs, this evaluation was performed for
16 individuals per group. The MEP results in the forelimbs
did not differ significantly, either for latency (p=0.09) or
amplitude values (p=0.20), and the hindlimbs also showed
no significant differences (p=0.85 and 0.08 respectively;
Table 3).
Table 4 shows the results of the histological analysis.
No significant difference was observed for necrosis, but the
other histological variables were significantly different among
the groups. The multiple comparison test (Mann-Whitney)
showed significant differences for hyperemia, hemorrhage,
degeneration of neural tissue and infiltration, as shown in
Table 5. Figure 1 shows examples of histological evaluations
and an example of a normal spinal cord.
’ DISCUSSION
One of the reasons why traumatic spinal cord injury is such
a devastating condition is that it leads to chronic impairment
and disability: it impairs the function of young accident
victims in the productive phase of their lives, and with the
aging of the population, it is also increasingly affecting the
elderly (1,34). Despite numerous advances in diagnostic tech-
nology, rehabilitation and surgical decompression therapies,
Table 2 - Multiple comparisons of BBB scores for limbs according
to the evaluation times from the second week after spinal cord
injury.
Day Reference group Comparison group p
14 CG CG 1
MG 0.37
G-CSF 0.02
G-CSF-M 0.07
MG CG 0.37
MG 1
G-CSF 0.17
G-CSF-M 0.01
G-CSF CG 0.02
MG 0.17
G-CSF 1
G-CSF-M o0.001
G-CSF-M CG 0.07
MG 0.01
G-CSF o0.001
G-CSF-M 1
21 CG CG 1
MG 0.2
G-CSF 0.51
G-CSF-M 0.01
MG CG 0.2
MG 1
G-CSF 0.02
G-CSF-M 0.14
G-CSF CG 0.51
MG 0.02
G-CSF 1
G-CSF-M o0.001
G-CSF-M CG 0.01
MG 0.14
G-CSF o0.001
G-CSF-M 1
28 CG CG 1
MG o0.001
G-CSF 0.14
G-CSF-M o0.001
MG CG o0.001
MG 1
G-CSF 0.02
G-CSF-M 0.05
G-CSF CG 0.14
MG 0.02
G-CSF 1
G-CSF-M o0.001
Table 2 - Continued.
Day Reference group Comparison group p
G-CSF-M CG o0.001
MG 0.05
G-CSF 0
G-CSF-M 1
35 CG CG 1
MG 0.01
G-CSF 0.04
G-CSF-M o0.001
MG CG 0.01
MG 1
G-CSF 0.13
G-CSF-M 0.01
G-CSF CG 0.04
MG 0.13
G-CSF 1
G-CSF-M o0.001
G-CSF-M CG o0.001
MG 0.01
G-CSF o0.001
G-CSF-M 1
42 CG CG 1
MG o0.001
G-CSF 0.02
G-CSF-M o0.001
MG CG o0.001
MG 1
G-CSF 0.27
G-CSF-M 0.01
G-CSF CG 0.02
MG 0.27
G-CSF 1
G-CSF-M o0.001
G-CSF-M CG o0.001
MG 0.01
G-CSF o0.001
G-CSF-M 1
CG = control group; MG = methylprednisolone group;
G-CSF = granulocyte colony-stimulating factor group and
G-CSF-M = group receiving G-CSF and methylprednisolone.
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which have reduced morbidity and mortality, improvements
in the therapeutic approach to secondary lesions are still
mostly experimental. No treatment has yet to provide a cure
or to facilitate complete functional recovery for patients with
spinal cord injury. In the present study, we explored whether
a combination of substances will have a better effect on
functional and histological recovery than one isolated drug,
possibly due to synergistic effects or to the fact that different
substances may act in different pathways as part of a com-
plex physiopathological process. This hypothesis proved to
be accurate: the combination of G-CSF and methylpredniso-
lone proved to be better than the control treatment and either
treatment alone, according to the functional evaluations from
the second week of treatment in rats. The functional results
were also better than those observed in other studies using
G-CSF alone (20,31).
Primary spinal cord injury develops into a secondary
injury via several biological processes, resulting in the impair-
ment of viable tissues and leading to necrosis and neuronal
apoptosis (16). The goal of pharmacological therapy is to
reduce or avoid secondary injury by inhibiting inflammation,
lipid peroxidation and excitotoxicity (35).
Several drugs have been studied in experimental and
clinical trials (2,9). Many drugs showed promising results in
experimental animal studies, but few have proven effective
in humans. Of these, methylprednisolone, tirilazad mesylate,
naloxone, and GM-1 ganglioside were evaluated in human
clinical trials in patients with spinal cord injury (36).
Methylprednisolone was the most extensively studied
drug (10,36). Although its mechanism of action is not fully
known, methylprednisolone has been shown to stabilize
membranes and preserve the hematospinal cord barrier, poten-
tially reducing vasogenic edema. It also increases spinal cord
blood flow, changes the electrolyte concentrations at the injury
site, inhibits endorphin release, reduces free radical availability,
and reduces the inflammatory response (11,36). Despite its
worldwide acceptance in the treatment of spinal cord injury,
methodological problems in clinical trials and new evidence
from clinical studies and literature reviews have raised con-
cerns about the small effect sizes of the clinical benefits, as
well as the risks of complications associated with the use of
methylprednisolone (36). Therefore, new studies should be
conducted with promising drugs, including but not limited
to methylprednisolone, tirilazad mesylate, naloxone and
Table 3 - Latency and amplitude values in the motor-evoked potential exam (means, standard deviations, minimum and maximum
values) of hindlimbs of rats subjected to experimental spinal cord lesion and comparisons between groups using the chi-squared and
Kruskal-Wallis tests.
Hindlimbs Groups N (limbs) Mean (ms) SD Min Max v2 DF p
Latency CG 16 27.83 8.77 15.80 40.30 6.626 3 0.85
MG 16 23.71 3.74 16.30 29.10
G-CSF 16 22.36 7.30 12.50 34.20
G-CSF-M 16 21.30 8.20 12.40 40.30
Amplitude CG 16 26.86 14.78 6.00 50.10 6.898 3 0.075
MG 16 43.98 65.22 4.70 276.80
G-CSF 16 64.71 92.85 10.90 312.10
G-CSF-M 16 97.43 115.58 4.70 483.00
CG = control group; MG = methylprednisolone group; G-CSF = granulocyte colony-stimulating factor group and G-CSF-M = group receiving G-CSF and
methylprednisolone.
Table 4 - Histological analysis scores according to the variables necrosis, hemorrhage, hyperemia, degeneration, and cellular infiltrate:
mean, minimum (min) and maximum (max) values, standard deviations (SD), degrees of freedom (DF) and chi-squared and Mann-
Whitney test results.
Variable Group N Mean score (0-3) SD Min Max v2 DF p
Necrosis CG 8 1.33 0.87 0 3 6.858 3 0.077
MG 8 0.92 0.5 0 2
G-CSF 8 1.04 0.46 0 2
G-CSF-M 8 0.83 0.48 0 2
Hemorrhage CG 8 1.54 0.72 1 3 14.23 3 0.003
MG 8 1.08 0.65 0 2
G-CSF 8 0.96 0.55 0 2
G-CSF-M 8 0.83 0.48 0 2
Hyperemia CG 8 1.83 0.64 1 3 22.51 3 o0.001
MG 8 1.38 0.65 0 2
G-CSF 8 1.25 0.61 1 3
G-CSF-M 8 0.96 0.46 0 2
Degeneration CG 8 1.92 0.65 1 3 16.9 3 0.001
MG 8 1.42 0.65 0 2
G-CSF 8 1.29 0.62 0 2
G-CSF-M 8 1.08 0.65 0 2
Cellular infiltrate CG 8 1.92 0.78 1 3 19.01 3 o0.001
MG 8 1.29 0.81 0 3
G-CSF 8 1.54 0.59 1 3
G-CSF-M 8 0.92 0.65 0 2
CG = control group; MG = methylprednisolone group; G-CSF = granulocyte colony-stimulating factor group and G-CSF-M = group receiving G-CSF and
methylprednisolone.
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GM-1 (36). G-CSF is also a promising drug in this field, as
interesting effects have been shown in clinical studies of
humans with spinal cord injury and thoracic myelopathy
(26,27).
We therefore decided to investigate G-CSF and methyl-
prednisolone together, compared with no therapy or with
either drug alone, in the treatment of rats with spinal cord
injury. We used a standardized experimental model that is
widely used in this field, which produced a contusion lesion
similar to the trauma most frequently seen in humans (34).
Because the sensitivity of other functional analyses is still
being evaluated (8), we used the BBB locomotor function
scale, a validated, reproducible and widely used tool for
assessing the recovery of rats after experimental spinal cord
injury (29,32). We also took care to ensure that the evaluators
performing the histological, functional and MEP analyses
were blinded to the experimental conditions and to each
other’s evaluations. Due to these standardized procedures,
the results can be compared with those of other studies.
The effect size of the improvement on the BBB locomotor
function scale for the G-CSF group was similar to that found
in other studies using the same methodology (20,31). Similar
to Kadota et al. (20), we used a dose of 15 mcg/kg/day of
G-CSF for five days. Dittgen et al. (31) used a higher dose
comprising a single 60 mcg bolus followed by 30 mg/kg/day
through an infusion pump. Considering that the functional
results of all these studies were similar, the benefit of the drug
can likely be achieved at lower doses and with a shorter
administration than that reported by Dittgen et al. (31).
In the present study, we found no difference between
groups in the MEP exam. MEP was chosen to evaluate the
function of the corticospinal tract (6). The absence of signi-
ficant differences in MEP in this study may be due to the
death of two animals per group, which reduced the size of
the final sample.
In the histological analysis, groups that received G-CSF,
with or without methylprednisolone, showed improved
hyperemia. All experimental groups had better results for
hemorrhage and degeneration than the control group. The
groups that received methylprednisolone, with or without
G-CSF, showed improvements in cellular infiltration. When
methylprednisolone was combined with G-CSF, all para-
meters improved, suggesting a synergistic effect between the
two drugs on the reduction of inflammation and main-
tenance of tissue architecture. These findings reinforce the
importance of combining different treatment modalities or
drugs for diseases with complex physiopathology, such as
spinal cord injuries.
Therefore, in clinical settings, different drugs with syner-
gistic effects can be administered at smaller doses when
combined, thereby improving efficacy and reducing side
effects. G-CSF has already been studied in humans in phase
I/IIa trials, with satisfactory results in the treatment of spinal
cord injury (26,27) and thoracic myelopathy. G-CSF should
be studied in phase III clinical trials. Further experimental
studies are needed to evaluate the efficacy and mechanism
of action underlying the synergistic effect of G-CSF and
methylprednisolone. The present study is somewhat limited
by the small sample size in each group. We were also unable
to address adverse effects or complications due to experi-
mental intervention.
The combination of methylprednisolone and G-CSF in the
treatment of experimental spinal cord contusion injury in rats
resulted in functional improvement, as assessed by the BBB
Table 5 - Multiple comparisons between groups in relation to
histological evaluation (Mann-Whitney test).
Groups Comparison Group p
Hyperemia CG CG 1.00
MG 0.608
G-CSF 0.002
G-CSF-M o0.001
MG CG 0.608
MG 1.000
G-CSF 0.311
G-CSF-M 0.011
G-CSF CG 0.002
MG 0.311
G-CSF 1.00
G-CSF-M 0.077
G-CSF-M CG o0.001
MG 0.011
G-CSF 0.077
G-CSF-M 1.000
Hemorrhage CG CG 1.00
MG 0.047
G-CSF 0.005
G-CSF-M o0.001
MG CG 0.047
MG 1.000
G-CSF 0.466
G-CSF-M 0.144
G-CSF CG 0.005
MG 0.466
G-CSF 1.00
G-CSF-M 0.419
G-CSF-M CG o0.001
MG 0.144
G-CSF 0.419
G-CSF-M 1.000
Degeneration CG CG 1.00
MG 0.019
G-CSF 0.003
G-CSF-M o0.001
MG CG 0.019
MG 1.000
G-CSF 0.448
G-CSF-M 0.076
G-CSF CG 0.003
MG 0.448
G-CSF 1.00
G-CSF-M 0.265
G-CSF-M CG o0.001
MG 0.076
G-CSF 0.265
G-CSF-M 1.000
Cellular infiltration CG CG 1.00
MG 0.016
G-CSF 0.088
G-CSF-M o0.001
MG CG 0.016
MG 1.00
G-CSF 0.288
G-CSF-M 0.089
G-CSF CG 0.088
MG 0.288
G-CSF 1.00
G-CSF-M 0.002
G-CSF-M CG o0.001
MG 0.089
G-CSF 0.002
G-CSF-M 1.000
CG = control group; MG = methylprednisolone group;
G-CSF = granulocyte colony-stimulating factor group and
G-CSF-M = group receiving G-CSF and methylprednisolone.
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scale, that was superior to the improvement obtained with
either methylprednisolone or G-CSF alone. The association of
methylprednisolone and G-CSF also had a synergistic effect
that resulted in an improvement in hyperemia and cellular
infiltration at the lesion site.
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